Biotinylated Human VEGF-C/Flt4-L Protein, Active
Beta LifeScience
SKU/CAT #: BLK-01210P-100UG

Biotinylated Human VEGF-C on Tris-Bis PAGE under reduced (R) condition. The purity is greater than 95%.
Biotinylated Human VEGF-C/Flt4-L Protein, Active
Beta LifeScience
SKU/CAT #: BLK-01210P-100UG
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Biotinylated Human VEGF-C/Flt4-L Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.It contains Thr103-Arg227. |
Purity | > 95% as determined by Tris-Bis PAGE |
Accession | Q6FH59 |
Target Symbol | VEGF-C/Flt4-L |
Synonyms | VEGFC; VEGFc; Flt4-L; VRP; VEGF-C |
Species | Human |
Expression System | HEK293 |
Tag | C-His-Avi |
Expression Range | Thr103-Arg227 |
Mol. Weight | The protein has a predicted MW of 17.1 kDa. Due to glycosylation, the protein migrates to 23-30 kDa based on Tris-Bis PAGE result. |
Form | Lyophilized |
Formulation | Lyophilized from 0.22um filtered solution in 50mM MES, 150mM NaCl (pH 6.0). Normally 8% trehalose is added as protectant before lyophilization. |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Biotinylated Human VEGF-C, His Tag at 1ug/ml (100ul/well) on the streptavidin precoated plate (5ug/ml). Dose response curve for Human VEGF R3, hFc Tag with the EC50 of 8.2ng/ml determined by ELISA. Contact us for detailed testing images. |
Storage | Reconstituted protein stable at -80°C for 12 months, 4°C for 1 week. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. |
Shipping | Shipped at ambient temperature. |
Gene Background | the lymphangiogenic factors vascular endothelial growth factor C (VEGFC) and VEGFD are cleaved by thrombin and plasmin, serine proteases generated during hemostasis and wound healing. Genetic studies reveal that platelet enhancement of lymphatic growth after wounding is dependent on the release of VEGFC, but not VEGFD, a finding consistent with high expression of VEGFC in both platelets and avian thrombocytes. |